ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Irvine et al., 2016 showed sonidegib treatment by itself or in combination with nilotinib (tyrosine kinase inhibitor against BCR-ABL oncogene of CML) reduced the self-renewal capacity of chronic phase (CP) CML in vitro and when engrafted to NSG mice [504].